How Avatar Can Enhance Autobiographical Memory of Patients With Substance Use Disorder

January 30, 2025 updated by: Fabio Frisone, Le.L.A.T. Lega Lotta Aids E Tossicodipendenza
The goal of this study is to investigate whether the use of artificial intelligence platforms can promote the retrieval of specific positive autobiographical memories.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The decision to focus on the retrieval of positive autobiographical memories was made for ethical reasons and is not tied to any specific research hypothesis. Specifically, the study aims to assess whether artificial intelligence facilitates the sharing of personal experiences and reflection on autobiographical memories related to substance use disorders, taking into account the potential influence of individual characteristics such as recent mood state, and overall memory functioning.

Study Type

Interventional

Enrollment (Actual)

42

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
      • Messina, Italy, 98124
        • Le.L.A.T. Lega Lotta Aids E Tossicodipendenza

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Clinical diagnosis of substance use disorder
  • Admitted to the drug rehabilitation center for at least 3 months
  • Aged 18 years or older

Exclusion Criteria:

  • Previous neurological pathologies
  • Previous cognitive deficits

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Avatar / Face-to-face
SUD patients were investigated using the Autobiographical Memory Test in two conditions: face-to-face and avatar-based interactions. Patients had to recall 6 neutral cue words and 6 substance-related cue words for each condition.
Device: avatar-based interactions
SUD patients were investigated using the Autobiographical Memory Test in two conditions: face-to-face and avatar-based interactions. Patients had to recall 6 neutral cue words and 6 substance-related cue words for each condition.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Specific Autobiographical Memory Recall
Time Frame: During the intervention sessions for both conditions (avatar-based and face-to-face). This outcome directly reflects the study's objective by quantifying the change of AM recall through avatar-based interventions.
The primary outcome measure is the difference in the number of specific autobiographical memories recalled between the avatar-based interaction condition and the face-to-face condition, as assessed by the Autobiographical Memory Test (AMT). Specificity of recalled memories are scored using standardized criteria. This measure evaluates the effectiveness of avatar-based interventions in changing AM recall in patients with substance use disorder (SUD).
During the intervention sessions for both conditions (avatar-based and face-to-face). This outcome directly reflects the study's objective by quantifying the change of AM recall through avatar-based interventions.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Latency of Autobiographical Memory Recall
Time Frame: During the intervention sessions for both conditions (avatar-based and face-to-face).
The secondary outcome measure is the comparison of latency times (time taken to recall a memory) between the avatar-based interaction condition and the face-to-face condition, as recorded during the Autobiographical Memory Test (AMT). This measure evaluates whether the use of avatar-based interventions change the speed of autobiographical memory recall in patients with substance use disorder (SUD).
During the intervention sessions for both conditions (avatar-based and face-to-face).
Pleasantness of Autobiographical Memories Recalled
Time Frame: During the intervention sessions for both conditions (avatar-based and face-to-face).
The secondary outcome measure is the comparison of pleasantness ratings of autobiographical memories recalled between the avatar-based interaction condition and the face-to-face condition. Pleasantness is assessed during the Autobiographical Memory Test (AMT). This measure evaluates whether avatar-based interventions change the emotional valence of the memories retrieved by patients with substance use disorder (SUD).
During the intervention sessions for both conditions (avatar-based and face-to-face).
Change in Age Memory Recall
Time Frame: During the intervention sessions for both conditions (avatar-based and face-to-face).
The secondary outcome measure is the change in age memory recall, defined as the participants' ability to identify the age at which autobiographical memories occurred, comparing the avatar-based interaction condition to the face-to-face condition. Age memory is assessed during the Autobiographical Memory Test (AMT) for each recalled memory. This measure evaluates whether avatar-based interventions change temporal specificity in autobiographical memory recall among patients with substance use disorder (SUD).
During the intervention sessions for both conditions (avatar-based and face-to-face).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Le.L.A.T. Lega Lotta Aids E Tossicodipendenza

Collaborators

Catholic University of the Sacred Heart

Investigators

  • Principal Investigator: Fabio Frisone, PhD, Catholic University of the Sacred Heart

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2024

Primary Completion (Actual)

December 15, 2024

Study Completion (Actual)

December 15, 2024

Study Registration Dates

First Submitted

January 27, 2025

First Submitted That Met QC Criteria

January 30, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 30, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MEM-AV

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

We plan to share the Individual Participant Data (IPD) starting from January 25, 2025. The data will be made available for research purposes to qualified researchers who submit a formal request and have an approved data-sharing agreement. Access will be contingent upon ensuring that proper data protection and confidentiality measures are followed, in compliance with ethical guidelines and applicable data protection laws. The data will not be shared for commercial purposes without further approval. The IPD will be made available for 5 years from the date of release.

IPD Sharing Time Frame

The data will become available starting from January 25, 2025. The data will remain available for 5 years from the date of release. Access to the data will be granted to qualified researchers upon request and following approval of a data-sharing agreement to ensure proper use and confidentiality.

IPD Sharing Access Criteria

Access to the data will be granted to qualified researchers who have a legitimate research purpose. Researchers must submit a formal request detailing the proposed study, its objectives, and the intended use of the data. Access will be contingent upon approval of a data-sharing agreement, which will outline the terms and conditions of use, including confidentiality and data security measures. The data will be provided only for research purposes and cannot be used for commercial purposes without further agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Substance Use Disorder (SUD)

Clinical Trials on avatar-based interactions

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe